In fact, a phase 1 clinical study is currently investigating the combination of an ALK‐TKI, ceritinib, with a MEK inhibitor, trametinib, in ALK+ or ROS1+ NSCLC patients [69]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.